

Partner of choice for the delivery of iPSC-based cell therapeutics



- Fully integrated platform to move iPSC-based cell therapy projects from inception to the clinic
- ▶ In-house GMP manufacturing capabilities, enabling a smooth transition into development and the clinic
- ▶ Extensive expertise and one of the largest iPSC teams in the industry
- A broad and innovative portfolio of early cell therapeutics projects available for partnering

Joining forces to drive the development of innovative and high-value product candidates

Evotec

- ▶ End-to-end platform, all under one roof
- ► Early innovation projects
- ▶ Research and development
- ▶ GMP manufacturing

Partner

- ▶ Clinical development
- ▶ Commercialization



ArrayCG

ArrayCGH, karyotyping, WGS



Single cell sequencing



3D expansion



Upscaling



Cell QC



GMP

Partnering opportunities

- ▶ Evotec is looking for strategic partners and collaborations to fully leverage our cell therapy platform and accelerate projects towards transformative therapies.
- ► Flexible collaborative models: From collaboration based on proprietary cell types, to development of new therapeutic cell types.
- ▶ Tailored and flexible partnership models.

Contact us

Victor Aguilar Lopez, PhD, MBA Sr. Director, Global BD Cell Therapy +33 (0)659 219 725 (mobile) Victor.AguilarLopez@evotec.com



From idea to the patient: End-to-end platform integrated under one roof

iPSC differentiation

- ▶ Industry-leading expertise
- ▶ Early GMP focus
- Validated GMP line
- ▶ State-of-the art analytical platform

Manufacturing & regulatory

- ▶ GMP-compatible bioreactor platform
- ► GMP gene editing & master cell bank
- ► Tox batch & clinical material
- Regulatory compliance
- Strong focus on 3D format

Genetic engineering

- Validated technology
- ▶ GMP-compatible process
- ► Cloaking & fail-safe technology for improved immune tolerance

Scientific excellence & disease expertise

- ► Large and dedicated team of experienced iPSC cell therapy scientists
- Disease expertise includes diabetes, immunooncology, CNS, auto-immune disease, fibrosis
- Broad range of tumor targeting moieties for oncology applications (CAR, TCR, ICE, antibody combo for ADCC)

Key benefits of Evotec's iPSC-based approach

Unlimited supply of starting material, on-demand availability Reduced manufacturing, logistics and associated COGS

Consistent quality of final product

Improved safety: cloaking and safety switch available Platform versatility, multiple cell types available

Experience matters – Evotec has the broadest proprietary iPSC pipeline in industry

	Field		Program/ Project	Disease area	Protocol	Pre-clinical research	Pre-clinical development	IND / Phase I	iPSC-derived cell types iNK Natural killer cells iT T cells
Part- nered	Cancer immunotherapy	Pharma	γδ iT	Oncology	Undisclosed	d			iMAC Macrophages iBeta Pancreatic islets iCM Cardiomyocytes iRPE Retinal pigment epithelium cells
	Metabolic disease	Sernova	E.iBeta (Device)	Diabetes					
Part- nering oppor- tunities	Cancer immunotherapy		iNK	Oncology					
			iMAC	Oncology		>			iPR Photoreceptors
			αβ iΤ	Oncology		>			Unpartnered programs/ projects are open for new business opportunities
	I&I¹		ίΝΚ, αβ ίΤ	Fibrosis, SLE ²		>			
	Metabolic disease		E.iBeta (Engineered)	Diabetes		*			
	Other		iCM	Heart failure					
			iRPE, iPR	Ophthalmology					

¹ Inflammation and Immunology

<u>Contact our experts</u> www.evotec.com

² Systemic Lupus Erythematosus

[▶] Each cell type can deliver multiple differentiated products